CASTOR

8:25
The definitive guide to multiple myeloma at ASH 2018: part I
Mohamad Mohty et al.
2:21
Updated CASTOR analysis: daratumumab plus Vd for R/R myeloma
Maria-Victoria Mateos
3:08
Carfilzomib for relapsed multiple myeloma: clinical trial updates
Katja Weisel
1:22
The importance of MRD status in MM
Niels van de Donk
1:54
CASTOR trial update: daratumumab/bortezomib/dexamethasone is an important regimen for R/R MM
Katja Weisel
2:42
Promising results for daratumumab in the front line setting
Philippe Moreau
3:22
Unprecedented clinical trial results for MM
Alberto Rocci
3:34
How effective are monoclonal antibodies at improving overall survival?
Philippe Moreau
1:56
Effective antibody therapy and updates from the POLLUX and CASTOR trials
Meletios Dimopoulos
2:13
Daratumumab in the treatment of multiple myeloma
Paul Richardson
3:19
What impact have new minimal residual disease (MRD) assessment techniques had in myeloma?
Nikhil Munshi
4:43
Immunotherapy highlights in multiple myeloma at ASH 2016
Niels van de Donk
4:11
Multiple myeloma highlights from ASCO 2016: monoclonal antibodies and oral proteasome inhibitors
Joseph Mikhael
3:51
Daratumumab in multiple myeloma: an overview of 3 key trials
Niels van de Donk
2:58
Why daratumumab is effective in multiple myeloma – results from the CASTOR trial
Antonio Palumbo
3:12
Results of Phase III POLLUX trial on daratumumab in multiple myeloma
Noopur Raje
The content of VJHemOnc is intended for healthcare professionals